Chronic Myelogenous Leukemia

References

• Craigie D. Case of disease of the spleen, in which death took place in consequence of the presence of purulent matter in the blood. Edinburgh Med Surg J 1854; 64: 400–413
   Google Scholar
• Bennett J. H. Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood. Edinburgh Med Surg J 1845; 64: 413–423
   Google Scholar
• Virchow R. Weisses blut. Froiep Notizen 1845; 36: 151–156
   Google Scholar
• Surveillance Epidemiology End Results Incidence and Mortality Data: 1973–1977. NCI Monograph 57, National Cancer Institute, Bethesda, Md 1981; 10
   Google Scholar
• Lange R. D., Moloney W. C., Yamawaki T. Leukemia in atomic bomb survivors. I. General Observations. Blood 1954; 9: 574–585
   PubMed Web of Science ®Google Scholar
• Heyssel R., Brill A. B., Woodbury L. A., et al. Leukemia in Hiroshima atomic bomb survivors. Blood 1960; 15: 113–31
   Google Scholar
• Court Brown W. M., Abbatt J. D. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J 1965; 2: 1327–1329
   PubMed Web of Science ®Google Scholar
• Goh K., Swisher S. N., Herman E. C., Jr. Chronic myelocytic leukemia in identical twins: Additional evidence of the Philadelphia chromosome as postzygotic abnormality. Arch Intern Med 1967; 120: 214–219
   PubMed Web of Science ®Google Scholar
• Jacobs E. M., Luce J. K., Caileau R. Chromosome abnormalities in human cancer: Report of a patient with chronic myelocytic leukemia and his nonleukemic monozygotic twin. Cancer 1966; 19: 869–876
   PubMed Web of Science ®Google Scholar
• Koeffler H. P., Golde D. W. Chronic myelogenous leukemia—New concepts. N Engl J Med 1981; 304: 1201–1209; 1269–1274
   PubMed Web of Science ®Google Scholar
• Suri R., Goldman J. M., Catovsky D. Priapism complicating chronic granulocyte leukemia. Am J Hematol 1980; 9: 295
   PubMed Web of Science ®Google Scholar
• Schafer Al. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1
   PubMed Web of Science ®Google Scholar
• Morley A. A., Baikie A., Gallon D. AG. Cyclic leucocytosis as evidence for retention of normal homeostatic control in chronic granulocytic leukaemia. Lancet 1967; 2: 1320–1323
   PubMed Web of Science ®Google Scholar
• Vodopick H., Rupp E., Edward C. L., et al. Spontaneous cyclic leukocytosis and thrombocytosis in chronic granulocytic leukemia. N Engl J Med 1972; 286: 284–290
   PubMed Web of Science ®Google Scholar
• Mitus W. J., Bergna L. J., Mednicoff I. B., et al. Alkaline phosphatase of mature neutrophils in chronic forms of myeloproliferative syndrome. Am J Clin Pathol 1958; 30: 285–294
   PubMed Web of Science ®Google Scholar
• Block J. B., Carbone P. P., Oppenheim J. J., et al. The effect of treatment in patients with chronic myelogenous leukemia: biochemical studies. Ann Intern Med 1963; 59: 629–636
   PubMed Web of Science ®Google Scholar
• Gilbert H. S., Krauss S., Pasternack B., et al. Serum vitamin B12 content and unsaturated vitamin B12 binding capacity in myeloproliferative disease. Ann Intern Med 1969; 71: 719
   PubMed Web of Science ®Google Scholar
• Fialkow P. J., Gartler S. M., Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 1967; 58: 1468–1471
   PubMed Web of Science ®Google Scholar
• Barr R. D., Fialkow P. J. Clonal origin of chronic myelocytic leukemia. N Engl J Med 1973; 289: 307–309
   PubMed Web of Science ®Google Scholar
• Fialkow P. J., Jacobson R. J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977; 63: 125–130
   PubMed Web of Science ®Google Scholar
• Beultler E., Yeh M., Fairbanks V. F. The normal female as a mosaic of X-chromosome activity: studies using the gene for G-6-PD-deficiency as a marker. Proc Natl Acad Sci USA 1962; 48: 9–16
   PubMed Web of Science ®Google Scholar
• Lyon M. F. Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet 1962; 14: 135–48
   PubMed Web of Science ®Google Scholar
• Nowell P. C., Hungerford D. A. Chromosome studies on normal and leukemic human leukocytes. JNCI 1960; 25: 85–109
   PubMed Web of Science ®Google Scholar
• Caspersson T., Gahrton G., Lindsten J., et al. Identification of the Philadelphia chromosome on a number 22 by quinacrine mustard fluorescence analysis. Exp Cell Res 1970; 63: 238–240
   PubMedGoogle Scholar
• Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• Shtivelman E., Lifschitz B., Gale R. P., et al. Fused transcript of abl and ber genes in chronic myelogenous leukemia. Nature 1985; 315: 550–554
   PubMed Web of Science ®Google Scholar
• Konopka J. B., Watanabe S. M., Witte O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035–1042
   PubMed Web of Science ®Google Scholar
• Kloetzer W., Kurzrock R., Smith L., et al. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 1985; 140: 230–8
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Kloetzer W. S., Talpaz M., et al. Identification of molecular variants of p210bcr/abl in chronic myelogenous leukemia. Blood 1987; 70: 233–236
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Buck M. B., Talpaz M., et al. Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia negative chronic myelogenous leukemia. Ann Intern Med 1986; 105: 673–679
   PubMed Web of Science ®Google Scholar
• Bartram C. R., Kleihauer E., de Klein A., et al. C-abl and ber are rearranged in a Ph'-negative CML patient. EMBO J 1985; 4: 683–686
   PubMed Web of Science ®Google Scholar
• Morris C. M., Reeve A. E., Fitzgerald P. H., et al. Genomic diversity correlates with clinical variation in Ph'-negative chronic my-eloid leukaemia. Nature 1986; 320: 281–283
   PubMed Web of Science ®Google Scholar
• Bartran C. R. ber rearrangement without juxtaposition of c-abl in chronic myeloid leukemia. J Exp Med 1985; 162: 2175–2179
   PubMed Web of Science ®Google Scholar
• Dreazen O., Klisak I., Rassool F., et al. Do oncogenes determine clinical features in chronic myeloid leukaemia?. Lancet 1987; 1: 1402–1405
   PubMed Web of Science ®Google Scholar
• Wiederman L. M., Karhi K. K., Shivji M. K., et al. The correlation of breakpoint cluster region rearrangement and p210 phi/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases. Blood 1988; 71: 349–355
   PubMed Web of Science ®Google Scholar
• Shtalrid M., Talpaz M., Buck M., et al. Philadelphia-negative chronic myelogenous leukemia with ber rearrangement: Molecular analysis, clinical characteristics and response to therapy. J Clin Oncol 1988; 6: 1569–1575
   PubMed Web of Science ®Google Scholar
• Shtalrid M., Talpaz M., Buck M., et al. Chromosome abnormalities in human leukemia. Annu Rev Genet 1980; 14: 17–39
   PubMed Web of Science ®Google Scholar
• Clinical significance of chromosomal abnormalities in acute lymphoblastic leukemia. Cancer Genet Cytogenet 1981; 4: 111–137, Third International Workshop on Chromosomes in Leukemia, 1980
   PubMed Web of Science ®Google Scholar
• Whang-Peng J., Henderson R. S., Nnudsen T., et al. Cytogenetic studies in acute myelocytic leukemia with special emphasis on the occurrence of the Ph1 chromosome. Blood 1980; 36: 448–457
   Google Scholar
• Look A. T. The emerging genetics of acute lymphoblastic leukemia: Clinical and biologic implications. Semin Oncol 1985; 12: 92–104
   PubMed Web of Science ®Google Scholar
• Bloomfield C. D., Rowley J. D., Goldman Al, et al. Chromosomal abnormalities and their clinical significance in acute lympho-blastic leukemia. Third International Workshop on Chromosomes in Leukemia. Cancer Res 1983; 43: 868–873
   PubMed Web of Science ®Google Scholar
• Look A. T. The emerging genetics of acute lymphoblastic leukemia: Clinical and biologic implications. Semin Oncol 1985; 12: 92–104
   PubMed Web of Science ®Google Scholar
• Gaynor J., Chapman C., Little C., et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969. J Clin Oncol 1988; 6: 1014–1030
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Gutterman J. U., Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319: 990–998, In: Mechanisms of Disease, edited by FH Epstein
   PubMed Web of Science ®Google Scholar
• Rorenhuis S., Smets L. A., Slater R. M., et al. Distinguishing the Philadelphia chromosome of acute lymphoblastic leukaemia from its counterpart in chronic myelogenous leukaemia. N Eng J Med 1985; 313: 51
   PubMed Web of Science ®Google Scholar
• Erikson J., Griffin C. A., Ar-Rushdi A., et al. Heterogeneity of chromosome 22 breakpoint in Philadelphia positive (Ph1 +) acute lymphocytic leukemia. Proc Natl Acad Sci USA 1986; 83: 1807
   PubMed Web of Science ®Google Scholar
• Gale R. P., Goldman J. M. Rapid progress in chronic myelogenous leukemia (workshop letter). Leukemia 1988; 2: 321–324
   PubMed Web of Science ®Google Scholar
• De Klein A., Hagemeijer A., Bartram C. R. bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 1986; 68: 1369–1375
   PubMed Web of Science ®Google Scholar
• Chan L. C., Karhi K. K., Heisterkramp N., et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987; 325: 635–637
   PubMed Web of Science ®Google Scholar
• Hermens A., Heisterkamp N., von Lindern M., et al. Unique fusion of bcr alpha c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51: 33–40
   PubMed Web of Science ®Google Scholar
• Fainstein E., Marcelle C., Rosner A., et al. A new fused transcript in Philadelphia positive acute lymphocytic leukaemia. Nature 1987; 330: L386–388
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Shtalrid M., Romero P., et al. A novel c-abl protein in Ph1 positive acute lymphoblastic leukemia. Nature 1987; 235: 631–635
   Google Scholar
• Walker L. C., Ganesan T. S., Dhut S., et al. Novel chimeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature 1987; 329: 851–853
   PubMed Web of Science ®Google Scholar
• Rubin C. M., Carrino J. J., Dickler M. N., et al. Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1988; 85: 2795–799
   PubMed Web of Science ®Google Scholar
• Seeker-Walker L. M., Cooke H. MG, Browett P. J., et al. Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia. Blood 1988; 72: 784–791
   PubMed Web of Science ®Google Scholar
• Jain E., Arlin Z., Mertelsmann R., et al. Philadelphia chromosome and terminal transferase-positive acute leukemia: similarity of terminal phase of chronic myelogenous leukemia and de novo presentation. J Clin Oncol 1983; 1: 669–676
   PubMed Web of Science ®Google Scholar
• Catovsky E. Ph1 positive acute leukaemia and chronic granulocyte leukemia. One or two diseases. Br J Haematol 1979; 42: 493–498
   PubMed Web of Science ®Google Scholar
• Clarkson B., Ellis S., Little C., et al. Acute lymphoblastic leukemia in adults. Semin Oncol 1985; 12: 160–179
   PubMed Web of Science ®Google Scholar
• Marks S. M., Baltimore D., McCaffrey R. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia. N Engl J Med 1978; 298: 812–814
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Barrarani M., Russo D., et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988; 25: 49–61
   PubMed Web of Science ®Google Scholar
• Fialkow P. J., Jacobson R. J., Papayannopoulou T., et al. Chronic my-elocytic leukemia: Clonal origin in a stem cell common to the granulocyte erythrocyte, platelet and monocyte/macrophage. Am J Med 1977; 63: 125–130
   PubMed Web of Science ®Google Scholar
• Martin P. J., Najfeld V., Hansen J. A. Involvement of the B-lymphoid system in chronic myelognous leukaemia. Nature 1980; 287: 49–50
   PubMed Web of Science ®Google Scholar
• Nitta M., Kato Y., Strife A., et al. Incidence of involvement of the B and T lymphgocyte lineages in chronic myelogenous leukemia. Blood 1985; 66: 1053–1061
   PubMed Web of Science ®Google Scholar
• Bartram C. R., Raghavachar A., Anger B., et al. T lymphocytes lack rearrangement of the bcr gene in Philadelphia chromosome positive chronic myelocytic leukemia. Blood 1987; 69: 1682–1685
   PubMed Web of Science ®Google Scholar
• Fauser A. A., Kanz L., Brass K. G., et al. T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia. J Clin Invest 1985; 75: 1080–1082
   PubMed Web of Science ®Google Scholar
• Dreazen O., Canaani E., Gale R. P. Molecular biology of chronic myelogenous leukemia. Semin Hematol 1988; 25: 35–49
   PubMed Web of Science ®Google Scholar
• McLaughlin J., Chianese E., Witte O. N. In vitro transformation of immature hematopoietic cells by the p210 bcr/abl oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987; 84: 6558–62
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Van Etten R. A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Fialkow P. J., Martin P. J., Najfeld V. Evidence of a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58: 158–163
   PubMed Web of Science ®Google Scholar
• Martin P. J., Najfeld M. V., Fialkow P. J. B-lymphoid cell involvement in chronic myelogenous leukemia: implications for the pathogenesis of the disease (review article). Cancer Genet Cytogenet 1982; 6: 359–368
   PubMed Web of Science ®Google Scholar
• Sonta S., Sandberg A. A. Chromosomes and causation of human cancer and leukemia. XXVIII. Value of detailed chromosome studies on large numbers of cells in CML. Am J Hematol 1977; 3: 121–126
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Smith T. L., McCredie K. G., et al. Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326–1335
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Gomez G. A., Baccarani M., et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive granulocytic leukemia. Blood 1988; 72: 294–298
   PubMed Web of Science ®Google Scholar
• Sandberg A. A. The Chromosomes in Human Cancer and Leukemia. Elsevier North-Holland, New York 1980; 185
   Google Scholar
• Whang-Peng J., Knutsen T. Chromosomal abnormalities. Chronic Granulocytic Leukaemia, M. T. Shaw. Praeger, EastbourneUK 1982; 49
   Google Scholar
• Swolin B., Weinfeld A., Westin J., et al. Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to managment and disease progression. Cancer Genet Cytogenet 1985; 18: 65–79
   PubMed Web of Science ®Google Scholar
• Singh S., Wass J., Vincent P. C., et al. Significance of secondary cytogenetic changes in patients with Ph-positive chronic granulocytic leukemia in the acute phase. Cancer Genet Cytogenet 1986; 21: 209–220
   PubMed Web of Science ®Google Scholar
• Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988; 25: 20–34
   PubMed Web of Science ®Google Scholar
• Ahuja H., Var-El M., Advani S. H., et al. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1989; 86: 6783–6787
   PubMed Web of Science ®Google Scholar
• Mashal R., Shtalrid M., Talpaz M., et al. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990; 75: 180–189
   PubMed Web of Science ®Google Scholar
• Finlay C. A., Hinds P. W., Levine A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083–1093
   PubMed Web of Science ®Google Scholar
• Nigro J. M., Baker S. J., Preisinger A. C., et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705–708
   PubMed Web of Science ®Google Scholar
• Lane D. P., Benchimol S. p53 oncogene or anti-oncogene? (review). Genes Dev 1990; 4: 1–8
   PubMed Web of Science ®Google Scholar
• Wintrobe M. M., Lee G. R., Boggs D. R., et al. Chronic myeloid leukemia. Clinical Hematology, 8th ed. Lea & Febiger, Philadelphia 1981; 1565–1595, Chapter 64
   Google Scholar
• Darte J. M., Dacie J. V., McSorley J. GA. Pelger-like leucocytes in chronic myeloid leukemia. Acta Haematol (Basel) 1952; 12: 117
   Web of Science ®Google Scholar
• Langenhuijsen M. MAC. Neutrophils with ring-shaped nuclei in myeloproliferative disease. Br J Haematol 1984; 58: 277
   PubMedGoogle Scholar
• Matsuo T., Tomonoaga M., Kuriyama K., et al. Prognostic significance of the morphological dysplastic changes in chronic myelogenous leukemia. Leukemia Res 1986; 10: 331–337
   PubMed Web of Science ®Google Scholar
• Doan C. A., Reinhart H. L. The basophil granulocyte, basophilocytosis and myeloid leukemia basophil and “mixed granule” types: An experimental clinical and pathological study with the report of a new syndrome. Am J Clin Pathol 1941; 11: 1–33
   Google Scholar
• Mlynek M. L., Leder L. D. Lineage infidelity in chronic myeloid leukemia: Demonstration and significance of hybridoid leukocytes. Virchows Arch (Cell Pathol) 1986; 51: 107–114
   Google Scholar
• Odenberg H., Olofsson T., Olsson I. Granulocyte function in chronic granulocytic leukaemia. I. Bacterial and metabolic capabilities during phagocytosis in isolated granulocytes. Br J Haematol 1975; 29: 427–441
   PubMed Web of Science ®Google Scholar
• Broxmeyer H. D., Mendelsohn N., Moore M. AS. Abnormal granulocyte feedback regulation of colony forming and colony stimulating activity-producing cells from patients with chronic myelogenous leukemia. Leukemia Res 1977; 1: 3–12
   Web of Science ®Google Scholar
• Baker M. A., Taub R. N., Kanani A. Increased activity of a specific sialytransferase in chronic myelogenous leukemia. Blood 1985; 66: 1068–1071
   PubMed Web of Science ®Google Scholar
• Nojiri H., Takaaku F., Ohta M. Changes in glycosphingolipid composition during differentiation of human leukemic granulocytes in chronic myelogenous leukemia compared with in vitro granulocytic differentiation of human promyelocytic leukemia cell line HL-60. Cancer Res 1985; 45: 6100–6106
   PubMed Web of Science ®Google Scholar
• Oloffson T., Odenberg H., Olsson I. Granulocyte function in chronic granulocytic leukemia. II. Bactericidal capacity, phagocytic rate, oxygen consumption, and granule protein composition in isolated granulocytes. Blood 1976; 48: 581–593
   PubMed Web of Science ®Google Scholar
• Evans W. H., Bednarek J. M., Alvarez V. L. Direct analysis of differentiation proteins in normal and leukemic human granulocytosis by high-performance liquid chromatography. JNCI 1985; 75: 227–235
   PubMed Web of Science ®Google Scholar
• Bednarek J. M., Knight R. D., Taylor G., et al. Progressive loss of phenotypic proteins in mature granulocytes before the onset of blast crisis in human chronic myelogenous leukemia. JNCI 1988; 80: 251–257
   PubMed Web of Science ®Google Scholar
• Zingde S. M., Mungikar A. M., Chhajlani V., et al. Plasma membranes from normal and chronic myeloid leukemic granulocytes: Isolation and two dimensional polyacrylamide gel electrophoretic analysis. Cancer Biochem Biophys 1985; 7: 333–342
   PubMedGoogle Scholar
• Brandt L. Adhesiveness to glass and phagocytic activity of neutrophilic leukocytes in myeloproliferative disease. Scand J Haematol 1965; 2: 126–136
   PubMedGoogle Scholar
• Penny R., Gallon D. AG, Scott J. T., et al. Studies on neutrophile function. I. Physiological and pharmacological aspects. Br J Haematol 1966; 12: 623–633
   PubMed Web of Science ®Google Scholar
• Taub R. N., Baker M. A., Madyastha K. R. Masking of neutrophil surface lectin-binding sites in chronic myelogenous leukemia (CML). Blood 1980; 55: 294–298
   PubMed Web of Science ®Google Scholar
• Perillie P. E., Finch S. The local exudative cellular response in leukemia. J Clin Invest 1960; 39: 1353–1357
   PubMed Web of Science ®Google Scholar
• Senn H. J., Rhomberg W. U., Jungi W. F. Storung derleukozytaren. Abwehrfunktion als paraneoplastiches Syndrom bei Ham oblas-tosen. Schweiz Med Wochenscnr 1971; 101: 466–470
   PubMedGoogle Scholar
• Banerjee T. K., Senn H., Holland J. F. Comparative studies on localized leukocyte mobilization in patients with chronic myelocytic leukemia. Cancer 1972; 29: 637–644
   PubMed Web of Science ®Google Scholar
• Penny R., Gallon D. AG. Studies onneutrophil function. H. Palhological aspecls. Br J Haematol 1966; 12: 633–645
   PubMed Web of Science ®Google Scholar
• Rosner F., Valmont J., Kozinn P. J., et al. Leukocyte function in patients with leukemia. Cancer 1970; 25: 835–842
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Catovsky D. Function of the phagocytic leukocytes in leukemia. Br J Haematol 1972; 23(Suppl)223–230
   PubMedGoogle Scholar
• Whittaker J. A., Khurshid M., Hughes H. R. Neulrophil funclion in chronic granulocytic leukemia before and after busulphan Irealment. Br J Haematol 1974; 28: 541–549
   PubMed Web of Science ®Google Scholar
• Brandt L. Studies on the phagocytic activily of neutrophilic leukocytes with special reference to chronic myeloproliferalive conditions and megaloblastic anemia. Scand J Haematol 1976; 17(Suppl 2)41
   Google Scholar
• El-Maallem H., Flelcher J. Defective hydrogen-peroxide production in chronic granulocytic neutrophils. Br J Haematol 1979; 41: 49–55
   PubMed Web of Science ®Google Scholar
• Corberand J., Laharraque P., Deharrard B., et al. Phagocytosis in myeloproliferalive disorders. Am J Clin Palhol 1980; 74: 301–305
   PubMed Web of Science ®Google Scholar
• Anklesaria P. N., Advani S. H., Bhisey A. N. Studies on granulocyte functions in palienls with chronic myeloid leukemia. Tumori 1985; 71: 317–324
   PubMed Web of Science ®Google Scholar
• Anklesaria P. N., Advani S. H., Bhisey A. N. Defective chemotaxis and adherence in granulocytes from chronic myeloid leukemia (CML) patients. Leukemia Res 1985; 9: 641–648
   PubMed Web of Science ®Google Scholar
• Asano M., Kawahara I. Ullramicroscopic characteristics of bone marrow cells in human chronic myeloid leukemia. Med J Shin-shu Univ 1968; 13: 109–126
   Google Scholar
• Anderson D. R. Ultrastructure of normal and leukemic leukocytes in human peripheral blood. J Ullrastrucl Res, 9(Suppl)1–42
   PubMedGoogle Scholar
• Vainchenker W., Guichard J., Deschamps J. F. Megakaryocyle cultures in the chronic phase and in the blasl crisis of chronic myeloid leukaemia: Studies on the differentiation of the mega-karyocyle progenitors and on the maturation of megakaryocytes in vitro. Br J Haematol 1982; 51: 131–146
   PubMed Web of Science ®Google Scholar
• Kuto F., Nagaoka T., Watanabe Y. Chronic myelocytic leukemia: ultrastructural histopathology of bone marrow from patients in the chronic phase. Ultrastruc Pathol 1984; 6: 307–317
   PubMed Web of Science ®Google Scholar
• Nagaoka T., Kuto F., Watanabe Y., et al. Bone marrow sinus and cell egress in human leukaemia: A morphometric study of core biopsies using wide-field electron microscopy. Br J Haematol 1986; 63: 737–747
   PubMed Web of Science ®Google Scholar
• Tavassoli M. The marrow-blood barrier. Br J Haematol 1979; 41: 297–302
   PubMed Web of Science ®Google Scholar
• Pedersen B. Functional and biochemical phenotype in relation to cellular age of differentiated neutrophils in chronic myeloid leukaemia (annotation). Br J Haematol 1982; 51: 339–344
   PubMed Web of Science ®Google Scholar
• Anklesaria P. N., Bhisey A. N. Studies on elecgrophoretic mobility of leucocytes from chronic myeloid leukemia patients. Indian J Exp Biol 1985; 23: 609–612
   PubMed Web of Science ®Google Scholar
• Tornyos K. Phagocytic activity of cells of the inflammatory exudate in human leukemia. Cancer Res 1967; 27: 1756–1760
   PubMedGoogle Scholar
• Goto T., Nishikori M., Arlin Z., et al. Growth characteristics of leukemic and normal hematopoietic cells in Ph1 + chronic myelogenous leukemia and effects of intensive treatment. Blood 1982; 59: 793–808
   PubMed Web of Science ®Google Scholar
• Strife A., Clarkson B. Biology of chronic myelogenous leukemia: Is discordant maturation the primary defect?. Semin Hematol 1988; 25: 1–19
   PubMed Web of Science ®Google Scholar
• Strife A., Lambek C., Wisniewski D., et al. Proliferative potential of subpopulations of granulocyte-macrophage progenitor cells in normal subjects and chronic myelogenous leukemia patients. Blood 1983; 62: 389–397
   PubMed Web of Science ®Google Scholar
• Strife A., Lambek C., Wisniewski D., et al. Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Res 1988; 48: 1035–1041
   PubMed Web of Science ®Google Scholar
• Wisniewski D., Strife A., Atzpodien J., et al. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia. Cancer Res 1987; 47: 4788–4794
   PubMed Web of Science ®Google Scholar
• Clarkson B., Strife A. Discordant maturation in chronic myelogenous leukemia. Chronic Myelogenous Leukemia, A. B. Deisseroth, R. B. Arlinghaus. Marcel Dekker, New York 1991; 3–90
   Google Scholar
• Stohlman F., Jr. Kinetics of erythropoiesis. Regulation of He-matopoiesis. Vol. 1, Red Cell Production, A. S. Gordon. Appleton-Century-Crofts, New York 1970; 317–326, Chapter 14
   Google Scholar
• Wintrobe M. M., Lee G. R., Boggs D. R., et al. Erythropoiesis. Clinical Hematology, 8th ed. Lea & Febiber, Philadelphia 1981; 108–135, Chapter 64
   Google Scholar
• Sokal J. E., Baccarani M., Russo D., et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988; 25: 49–61
   PubMed Web of Science ®Google Scholar
• Gomez G. A., Herrmann R., Sokal J. E. Prognostic value of serial measurements of leukocyte thymidine uptake in well controlled chronic myelocytic leukemia. Leukemia Res 1981; 5: 497–503
   PubMed Web of Science ®Google Scholar
• Silver R. T., Moore M., Senterfit L., et al. Early recognition of terminal phase CML by serial chromosome and agar culture techniques, (abstract C-9). Proc AACR/ASCO 1978; 19: 309
   Google Scholar
• Sokal J. E., Cox E. B., Baccarani M., et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Alimena G., Dallapiccola B., Gastaldi R., et al. Chromosomal, morphological and clinical correlations in blastic crisis of chronic myeloid leukaemia. A study of 69 cases. Scand J Haematol 1982; 28: 103–117
   PubMedGoogle Scholar
• Bertanzzoni U., Brusamolino E., Isernia P., et al. Prognostic significance of terminal transferase and adenosine deaminase in acute and chronic myeloid leukemia. Blood 1982; 60: 685–692
   PubMed Web of Science ®Google Scholar
• Cervantes F., Ballesta F., Mila M., et al. Cytogenetic studies in blast crisis of Ph-positive chronic granulocytic leukemia: Results and prognostic evaluation in 52 patients. Cancer Genet Cytogenet 1986; 21: 239–246
   PubMed Web of Science ®Google Scholar
• Marianni G., Annino L., Solinas S., et al. Blastic transformation in chronic myelogenous leukemia: Experience with 50 patients. Med Pediatr Oncol 1978; 4: 159–167
   PubMedGoogle Scholar
• Zaccaria A., Ruggero D., Guolo M. L., et al. Ph'-positive chronic myeloid leukaemia presenting in blastic crisis: Report of 12 cases. Boll 1st Sieroter Milan 1978; 57: 383–391
   PubMedGoogle Scholar
• Kantarjian H. M., Smith T. L., McCredie K. G., et al. Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326–1355
   PubMed Web of Science ®Google Scholar
• Eisenberg A., Silver R., Soper L., et al. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia 1988; 2: 642–647
   PubMed Web of Science ®Google Scholar
• Mills K. I., MacKenzie E. D., Birnie G. D. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood 1988; 72: 1237–1241
   PubMed Web of Science ®Google Scholar
• Morris S. W., Daniel L., Ahmed C. MI, et al. Relationship of bcr breakpoint to chronic phase duration, survival and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 1990; 75: 2035–2041
   PubMed Web of Science ®Google Scholar
• Deazen O., Berman M., Gale R. P. Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase. Blood 1988; 71: 797–799
   PubMed Web of Science ®Google Scholar
• Shtalrid M., Talpaz M., Kurzrock R., et al. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood 1988; 72: 485–490
   PubMed Web of Science ®Google Scholar
• Gallon D. AG. Myleran in chronic myeloid leukaemia. Lancet 1953; 1: 208
   Google Scholar
• Haul A., Abbot W. S., Wintrobe M. M., et al. Busulfan in the treatment of chronic myelocytic leukemia: The effect of long term intermittent therapy. Blood 1961; 17: 1
   PubMed Web of Science ®Google Scholar
• Haddow A., Timmis G. M. Myleran in chronic myeloid leukaemia. Chemical constitution and biological action. Lancet 1953; 1: 207
   Google Scholar
• Feingold M. L., Koss L. G. Effects of long-term administration of busulfan. Arch Intern Med 1969; 124: 66
   PubMed Web of Science ®Google Scholar
• Fishbein W. N., Carbone P. P., Freireich E. J. Clinical trials of hy-droxyurea in patients with cancer and leukemia. Clin Pharmacol Ther 1964; 5: 574
   PubMed Web of Science ®Google Scholar
• Kennedy B. J. Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 1971; 29: 1052
   Web of Science ®Google Scholar
• Schwartz J. H., Canellos G. P. Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. Blood 1975; 46: 11
   PubMed Web of Science ®Google Scholar
• Bolin R. W., Robinson W. A., Sutherland J., et al. Busulfan vs hy-droxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 1982; 50: 1683–1686
   PubMed Web of Science ®Google Scholar
• Rushing D., Goldman J. M., Gibbs G., et al. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Am J Clin Oncol 1982; 5: 307–313
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Catovsky D., Hows J., et al. Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukemia in transformation. Br Med J 1979; 1: 1310–1313
   PubMed Web of Science ®Google Scholar
• Goldman J. N., Perley J. F., Jones L., et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314: 202–207
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., Kurzrock R., et al. Therapy of chronic myelogenous leukemia: Chemotherapy and interferons. Semin Hematol 1988; 25: 62–73
   PubMed Web of Science ®Google Scholar
• Brodsky I., Fuscaldo K. E., Kahn S. B., et al. Chronic myelogenous leukemia: A clinical and experimental evaluation of splenectomy and intensive chemotherapy. Ser Haematol 1975; 6: 143
   Google Scholar
• Clarkson B. Chronic myelogenous leukemia: Is aggressive treatment indicated?. J Clin Oncol 1985; 3: 135
   PubMed Web of Science ®Google Scholar
• Denz H., Lechleitner M., Marth C. H., et al. Effects of human re-combinant alpha-2-and gamma interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J Interferon Res 1985; 5: 147
   PubMedGoogle Scholar
• Sharp J. C., Wayne A. W., Crofts M., et al. Karyotypic conversion in Ph'-positive chronic myeloid leukaemia with combination chemotherapy. Lancet 1979; 1: 1370
   PubMed Web of Science ®Google Scholar
• Smalley R. V., Vogel J., Huguley C. M., et al. Chronic granulocytic leukemia: Cytogenetic conversion of the bone marrow with cycle-specific chemotherapy. Blood 1977; 50: 107
   PubMed Web of Science ®Google Scholar
• Borden E. C., Fall L. A. Interferons: Biochemical, cell growth, inhibitory and immunological effects. Prog Hematol 1981; 350: 1
   Google Scholar
• Talpaz M., Kantarjian H. M., McCredie K. G., et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280–1288
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., McCredie K., et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Mannheim H., Heimpel B., et al. Prospective controlled comparison of busulfan vs hydroxyurea vs interferon alpha in chronic myelogenous leukemia (CML) (abstract 1105). Blood 1990; 76(Suppl 1)279
   PubMedGoogle Scholar
• Silver R. T., Reich S. D., Coleman M., et al. Gamma interferon (IFN) has activity in treating chronic myeloid leukemia (CML) (abstract 808). Blood 1986; 68(Suppl 1)232
   Google Scholar
• Kantarjian H. M., Talpaz M., Keating M. J. Chronic myelogenous leukemia in accelerated and blastic phases: Present statues and future prospects. Chronic Myelogenous Leukemia—Molecular Approaches to Research and Therapy, A. B. Deisseroth, R. B. Arlinghous. The University of Texas MD Anderson Cancer Center, Houston 1991, Chapter 18
   Google Scholar
• Thomas E. D., Clift R. A., Fefer A., et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155–163
   PubMed Web of Science ®Google Scholar
• Martin P. J., Hansen J. A., Buckner C. D., et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664–672
   PubMed Web of Science ®Google Scholar
• Apperley J. F., Jones L., Hale G., et al. Bone marrow transplantation for chronic myeloid leukemia: T cell depletion reduces the risk of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986; 1: 53–66
   PubMed Web of Science ®Google Scholar
• Apperley J. F., Mauro F. R., Goldman J. M., et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronicphase: Importance of a graft-versus-host leukaemia effect. Br J Haematol 1988; 69: 239–245
   PubMed Web of Science ®Google Scholar
• Apperley J. F., Jones F., Hale G., et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986; 1: 53–66
   PubMed Web of Science ®Google Scholar
• Martin P. J., Hansen J. A., Buckner C. D., et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664–672
   PubMed Web of Science ®Google Scholar
• Prentice H. G., Blacklock H. A., Janossy G., et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1985; 1: 472–475
   Web of Science ®Google Scholar
• Reisner Y., Kapoor R. J., Kirkpatrick N., et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981; 2: 327–331
   PubMed Web of Science ®Google Scholar
• Cunningham I., Castro-Malaspina H., Flomenberg N., et al. T-cell depleted bone marrow transplant for chronic myelogenous leukemia. Blood 1988; 72: 384a
   Google Scholar
• Goldman J. M., Gale R. P., Horowitz M. M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T cell depletion. Ann Intern Med 1988; 108: 806–184
   PubMed Web of Science ®Google Scholar
• Cunningham I. Bone marrow transplantation for chronic myelogenous leukemia. Oncology 1990; 4: 101–111
   PubMedGoogle Scholar
• Carabasi M. H., Young J. W., Kernan N. A., et al. Initial results with T-cell depleted allogeneic bone marrow transplants following TBI/VP-16/cyclophosphamide in patients with chronic myelogenous leukemia in first chronic or early accelerated phase (abstract 2114). Blood 1990; 76(Suppl 1)
   Google Scholar
• Aversa F., Pelicci P. G., Terenzi A., et al. Results of T-depleted BMT in chronic myelogenous leukaemia after a conditioning regimen that included thiotepa. Bone Marrow Transplant 1991; 7(Suppl 2)24
   PubMedGoogle Scholar
• Thomas E. D., Clift R. A. Indications for marrow transplantation in chronic myelogenous leukemia (perspective). Blood 1989; 73: 861–864
   PubMed Web of Science ®Google Scholar
• Tutschka P., Copelan E. A., Klein J. P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388
   PubMed Web of Science ®Google Scholar
• Copelan E. A., Grever M. R., Kapoor N., et al. Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukaemia in accelerated or blastic phase. Br J Haematol, 71: 487–491
   PubMed Web of Science ®Google Scholar
• Beatty P. G., Clift R. A., Mickelson, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765–771
   PubMed Web of Science ®Google Scholar
• McGlave P. B., Beatty P., Ash R., et al. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: Results in 102 cases. Blood 1990; 75: 1728–1732
   PubMed Web of Science ®Google Scholar
• Haines M. E., Goldman J. M., Worsley A. M., et al. Chemotherapy and autografting for patients with chronic granulocytic leukaemia in transformation: Probable prolongation of life for some patients. Br J Haematol 1984; 58: 711–722
   PubMed Web of Science ®Google Scholar
• Buckner C. D., Clift R. A., Fefer A., et al. Treatment of blastic transformation of chronic granulocytic leukemia by high dose cyclophosphamide, total-body irradiation and infusion of cryo-preserved autologous marrow. Exp Hematol 1978; 6: 96–109
   PubMed Web of Science ®Google Scholar
• Buckner C. D., Steward P., Clift R. A., et al. Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 1978; 6: 96–109
   PubMed Web of Science ®Google Scholar
• DeFabritiis P., Sandrelli A., Meloni G., et al. Prolonged suppression of myeloid progenitor cell numbers after stopping inter-feron treatment for CML necessitates delay in harvesting marrow cells for autografting. Bone Marrow Transplant 1990; 6: 247–251
   PubMed Web of Science ®Google Scholar
• Barnett M. J., Eaves C. J., Phillips G. L., et al. Successful autografting in chronic myeloid leukemia after maintenance of marrow in culture. Bone Marrow Transplant 1989; 4: 345–351
   PubMed Web of Science ®Google Scholar
• Chang J. Data presented at the British Society of Haematology Meeting, CanterburyUK, April, 1989
   Google Scholar
• Brito-Babapulle F., Bowcock S. J., Marcus R. E., et al. Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Haematol 1989; 73: 76–81
   PubMed Web of Science ®Google Scholar